Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. / INSIGHT START Study Group.

In: Journal of the International AIDS Society, Vol. 22, No. 6, e25297, 06.2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

INSIGHT START Study Group 2019, 'Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study', Journal of the International AIDS Society, vol. 22, no. 6, e25297. https://doi.org/10.1002/jia2.25297

APA

INSIGHT START Study Group (2019). Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. Journal of the International AIDS Society, 22(6), [e25297]. https://doi.org/10.1002/jia2.25297

Vancouver

INSIGHT START Study Group. Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. Journal of the International AIDS Society. 2019 Jun;22(6). e25297. https://doi.org/10.1002/jia2.25297

Author

INSIGHT START Study Group. / Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. In: Journal of the International AIDS Society. 2019 ; Vol. 22, No. 6.

Bibtex

@article{290c94e0a69943bc96279fd12d9914a1,
title = "Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study",
abstract = "INTRODUCTION: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflammation. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was the objective of this study.METHODS: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the CD4+/CD8+ T-cell ratio, were analysed at baseline and eight months after ART initiation in treatment-na{\"i}ve participants with HIV and CD4+ T-cells >500 cells/mm3 enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in participants who achieved virologic suppression (<50 copies/mL).RESULTS: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the period between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/mm3 . Incomplete adherence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other biomarkers were observed.CONCLUSIONS: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppression early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number: NCT00867048.",
author = "Castillo-Mancilla, {Jose R} and Phillips, {Andrew N} and Neaton, {James D} and Jacqueline Neuhaus and Shweta Sharma and Baker, {Jason V} and Simon Collins and Sharon Mannheimer and Sarah Pett and Veronique Touzeau-R{\"o}mer and Polizzotto, {Mark N} and Lundgren, {Jens D} and Gardner, {Edward M} and {INSIGHT START Study Group}",
note = "{\textcopyright} 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.",
year = "2019",
month = jun,
doi = "10.1002/jia2.25297",
language = "English",
volume = "22",
journal = "International AIDS Society. Journal",
issn = "1758-2652",
publisher = "BioMed Central Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study

AU - Castillo-Mancilla, Jose R

AU - Phillips, Andrew N

AU - Neaton, James D

AU - Neuhaus, Jacqueline

AU - Sharma, Shweta

AU - Baker, Jason V

AU - Collins, Simon

AU - Mannheimer, Sharon

AU - Pett, Sarah

AU - Touzeau-Römer, Veronique

AU - Polizzotto, Mark N

AU - Lundgren, Jens D

AU - Gardner, Edward M

AU - INSIGHT START Study Group

N1 - © 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

PY - 2019/6

Y1 - 2019/6

N2 - INTRODUCTION: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflammation. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was the objective of this study.METHODS: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the CD4+/CD8+ T-cell ratio, were analysed at baseline and eight months after ART initiation in treatment-naïve participants with HIV and CD4+ T-cells >500 cells/mm3 enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in participants who achieved virologic suppression (<50 copies/mL).RESULTS: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the period between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/mm3 . Incomplete adherence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other biomarkers were observed.CONCLUSIONS: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppression early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number: NCT00867048.

AB - INTRODUCTION: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflammation. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was the objective of this study.METHODS: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the CD4+/CD8+ T-cell ratio, were analysed at baseline and eight months after ART initiation in treatment-naïve participants with HIV and CD4+ T-cells >500 cells/mm3 enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in participants who achieved virologic suppression (<50 copies/mL).RESULTS: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the period between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/mm3 . Incomplete adherence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other biomarkers were observed.CONCLUSIONS: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppression early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number: NCT00867048.

U2 - 10.1002/jia2.25297

DO - 10.1002/jia2.25297

M3 - Journal article

C2 - 31250552

VL - 22

JO - International AIDS Society. Journal

JF - International AIDS Society. Journal

SN - 1758-2652

IS - 6

M1 - e25297

ER -

ID: 236270343